课题基金 / 基金详情

STUDY OF THE SAFETY AND PHARMACOKINETIC PROFILES OF RECOMBINANT RHUMAB VEGF

STUDY OF THE SAFETY AND PHARMACOKINETIC PROFILES OF RECOMBINANT RHUMAB VEGF
重组 RHUMAB VEGF 的安全性和药代动力学特征研究
批准号：
6279049
负责人：
Michael Gordon
金额：
$1.68万
依托单位：
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-12-01 至 1998-11-30
来源：
https://reporter.nih.gov/project-details/6279049
关键词：
clinical research clinical trial phase I drug screening /evaluation human subject monoclonal antibody neoplasm /cancer chemotherapy pharmacokinetics recombinant proteins vascular endothelial growth factors

项目摘要

项目成果

Michael Gordon的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
rhuMAb VEGF is an experimental humanized monoclonal antibody produced by Genentech using recombinant DNA technology. Antibodies are proteins that can protect the body from foreign invaders, such as bacteria and viruses. rhuMAb VEGF is a monoclonal antibody to vascular endothelial growth factor (VEGF), which is present in a wide variety of normal tissues but is produced in excess by most solid cancers (tumors)> In the setting of cancer, VEGF promotes the growth of blood vessels that bring nutrients to the tumor cells. In laboratory studies, rhuMAb VEGF inhibits the growth of many different cancers in animals by blocking the effects of VEGF.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PHASE I TRIAL OF MINOCYCLINE IN PATIENTS WITH CANCER
PHASE I STUDY OF BB 10010 IN PATIENTS WITH RELASPED/REFRACTORY BREAST CANCER
STUDY OF THE SAFETY AND PHARMACOKINETIC PROFILES OF RECOMBINANT RHUMAB VEGF
STUDY OF THE SAFETY AND PHARMACOKINETIC PROFILES OF RECOMBINANT RHUMAB VEGF
海外基金